Comprehensive Analysis of Vascular Endothelial Growth Factor-C Related Factors in Stomach Cancer

Yong-Chao Liu1&, Jing Zhao2&, Cheng-En Hu1, Jun Gan1, Wen-Hong Zhang2*, Guang-Jian Huang1*

Abstract

Background: Vascular endothelial growth factor-C (VEGF-C), which contributes to lymphatic metastasis (LM) in malignant disease, is one of the most important factors involved in physical and pathological lymphangiogenesis. Some VEGF-C related factors such as sine oculis homeobox homolog (SIX) 1, contactin (CNTN) 1 and dual specificity phosphatase (DUSP) 6 have been extensively studied in malignancies, but their expression levels and associations have still to be elucidated in stomach cancer.

Methods: We detected their expression levels in 30 paired stomach cancer tissues using quantitative real-time reverse transcription-PCR (qRT-PCR). The expression and clinical significance of each factor was analyzed using Wilcoxon signed rank sum test. The correlation among all the factors was performed by Spearman rank correlation analysis.

Results: The results suggest that VEGF-C and CNTN1 are significantly correlated with tumor size, SIX1 with the age and CNTN1 also with the cTNM stage. There are significant correlations of expression levels among VEGF-C, SIX1, CNTN1 and DUSP6.

Conclusions: There exists an important regulatory crosstalk involving SIX1, VEGF-C, CNTN1 and DUSP6 in stomach cancer.

Keywords: Stomach neoplasms - VEGF-C - SIX1 - CNTN1 - DUSP6 - crosstalk

Asian J Cancer Prev, 15 (5), 1925-1929

Introduction

Stomach cancer, the fourth most common cancer worldwide in men and the fifth in women, is one of the most fatal diseases (Guggenheim and Shah, 2012). VEGF-C correlates with lymphatic metastasis (LM) in many malignancies, including stomach cancer (Achen and Stacker, 2008; Wang et al., 2012). VEGF-C is proteolytically processed, binds VEGFR-3 and induces tyrosine autophosphorylation of VEGFR-3 and VEGFR-2 (Joukov et al., 1996; Joukov et al., 1997). VEGF/VEGFR-3 axis plays an important role in cancer metastasis (Su et al., 2006; Su et al., 2007; Achen and Stacker, 2008; Cao, 2008; Peng et al., 2011), and is significantly related to prognosis in diverse malignant disease, like breast cancer (Zhu et al., 2011; Wang et al., 2012), prostatic cancer (Jennbacken et al., 2005) and so on.

SIX protein family, with 6 members, is highly conserved through various organisms that range from flatworms to human (Kumar, 2009). SIX1 is one of the members implicated in carcinogenesis through various mechanisms among which VEGF is involved (Christensen et al., 2008; Kumar, 2009; Wang et al., 2012). Wang (Wang et al., 2012) et al demonstrated that both in vitro and in vivo SIX1 could directly activate VEGF transcription by binding to specific DNA sequences in the VEGF promoter.

Besides molecules inducing VEGF-C expression, there are many proteins can be induced by VEGF-C/VEGFR3 axis such as CNTN1, which is increased by activation of the VEGF-C/VEGFR3 axis and is required for the axis-mediated cell mobility and metastasis in different types of cancer cells (Su et al., 2006).

Moreover, VEGF-C can be induced by MAKP pathways (Tsai et al., 2003). Among all the members involved in MAKP pathways, phosphorylated extracellular signal-regulated kinase (ERK) 1/2 is critical for insulin-like growth factor-1-induced VEGF-C upregulation (Zhu et al., 2011). As a negative regulator of MAKP pathways, DUSP6 can directly inhibit the phosphorylation of ERK1/2 (Maillet et al., 2008; Cejudo-Marin et al., 2012), which can transcriptionally activate DUSP6, that constitutes a feedback regulatory loop between ERK 1/2 and DUSP6 (Furukawa et al., 2008). Intriguingly, SIX1 can also regulate the ERK1/2 pathway by directly controlling DUSP6 transcription (Le Grand et al., 2012).

According to previous reports, there are complicated regulatory networks among VEGF-C, SIX1, CNTN1 and DUSP6 as summarizing in Figure 1. Given the confirmed importance of VEGF-C and the lack of study about VEGF-C related factors mentioned above in stomach cancer, we firstly perform this study to evaluate the significance of VEGF-C and its related factors (SIX1, CNTN1 and DUSP6) in stomach cancer.

1Department of General Surgery; 2Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China *Equal contributors *For correspondence: guangjian_huang@163.com, zhangwenhong@fudan.edu.cn

Asian Pacific Journal of Cancer Prevention, Vol 15, 2014 1925
**Materials and Methods**

**Patients**

All paired pathological samples were collected from 30 stomach cancer patients from 2012.11 to 2013.7 in Fudan university affiliated Huashan Hospital. Each sample pair included a piece of cancer specimen and a piece of normal tissue. They were all confirmed as cancer or normal tissue respectively by two pathologists. All samples were stored in liquid nitrogen immediately within 30 minutes after stomach resection until RNA extraction.

All 30 tumor tissues were identified as adenocarcinoma. Totally, there were 19 male patients and 11 female patients, with the age of 35 to 77, and on an average of 57.5. One was classified as stage 1, 0 as stage II, 15 as stage III and 1 as stage IV in accordance with cTNM Cancer Staging Manual released by American Joint Committee on Cancer. One was well differentiated, 5 were moderate and 24 were poor according to their differentiation status.

All patients enrolled in this study were informed and consent was given.

**Total RNA extraction**

Total RNA was extracted using the TRizol reagent (Invitrogen, CA) as described previously (Liu et al., 2011). RNA quantity and quality were determined by Nanodrop2000.

**Reverse transcription and qRT-PCR**

Reverse transcription was performed using the PrimeScript™ RT reagent kit (TaKaRa, Dalian, China). The cDNA template was amplified by qRT-PCR using the SYBR OR Premix EX Taq™ II kit (TaKaRa). The thermal cycling conditions were as follows: 95°C for 60 s followed by 40 cycles of 95°C for 5 s and 60°C for 34 s. After amplification, the products were subjected to an increasing temperature gradient from 60 to 95°C. Plates were held for 1 s and read every 0.4°C to create a melting curve. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) mRNA was used as an internal control to normalize input mRNA level.

The primer sequences are as follows: SIX1-forward-5'-AGGAAAGGGAGACACCCGAAA-3', reverse-5'-CCCTTCCAGAGGAGAGTTG-3'; VEGFC-forward-5'-TCATCTCCATTAGAGCTTCCCTG-3', reverse-5'-TCCTGACGTTCACTCCAGCT-3'; CNTN1-forward-5'-GCCAATTACATTACATTATCCAG-3', reverse-5'-AACAAAGTTTTCTCCTTACATAC-3'; DUSP6-forward-5'-ACCAATCCGTGATACCTCGACAGCT-3', reverse-5'-GCTGTCGTCTAGGCACACAGT-3'; GAPDH-forward-5'-CCTCTAGCTTGAGCTTCTTGA-3', reverse-5'-GCTGTCGTCTAGGCACACAGT-3'; SIX1-forward-5'-CAAAAATCCGTGATACCTCGACAGCT-3', reverse-5'-GCTGTCGTCTAGGCACACAGT-3'.

**Statistical Analysis**

All data were analyzed by SAS 8.0. The expression and clinical significance of each factor was analyzed using Wilcoxon signed rank sum test. The correlation among all the factors was performed by Spearman rank correlation analysis. P value <0.05 was considered statistically significant.

**Results**

**Deregulation of VEGFC, SIX1, CNTN1 and DUSP6**

We found that mRNA levels of VEGFC, SIX1, CNTN1 and DUSP6 varied a lot among 30 paired stomach cancer tissues. All the factors were not significantly deregulated (Table 1). VEGFC, SIX1, CNTN1 and DUSP6 were upregulated in 36.7%, 33.3%, 20.0% and 43.2% of stomach cancer cases respectively (Table 1).
Comprehensive Analysis of Vascular Endothelial Growth Factor-C Related Factors in Stomach Cancer

Table 4. The Correlation among VEGFC and its Related Factors

| Items            | rs (p value)      | SIX1 | VEGFC | CNTN1 | DUSP6 |
|------------------|-------------------|------|-------|-------|-------|
|                  |                   |      |       |       |       |
| Gender           |                   |      |       |       |       |
| Male             | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| Female           | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| Age (years)      |                   |      |       |       |       |
| ≤65              | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| >65              | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| Diameter(cm)     |                   |      |       |       |       |
| ≤4               | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| >4               | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| cTNM             |                   |      |       |       |       |
| 0                | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| I                | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| II               | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| III              | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| IV               | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| Differentiation  |                   |      |       |       |       |
| Well             | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |
| Poor             | 0.66274 (<0.0001) |      | 0.53281 (0.0024) | 0.15729 (0.4065) |

The association between expression level with clinical and pathological characteristics

The clinical and pathological characteristics were presented as Table 2. The expression of SIX1 was significantly correlated with patients’ age (Table 3). Both VEGFC and CNTN1 were profoundly correlated with the tumor size (Table 3). CNTN1 was also correlated with patients’ cTNM staging (Table 3).

The association among each VEGFC related factors

The expression of SIX1, CNTN1 and DUSP6 were all significantly correlated with that of VEGFC (Table 4). Besides, SIX1’s expression was significantly correlated with that of CNTN1 (Table 4). There was no obvious correlation between SIX1 and DUSP6 (Table 4).

Discussion

There was no factor significantly deregulated in our study, we thought that is because of the limited cases and the lack of follow-up information. Yet the results still provided us with some interesting implications. VEGFC is known for its irreplaceable role in lymphangiogenesis (Alitalo and Carmeliet, 2002), which is one of the mechanisms contributing to LM (Achen and Stacker, 2008). In our study, VEGFC was upregulated in 36.7% (Table 1) patients, which is in accordance with Arigami and Amioka’s reports (Amioka et al., 2002; Arigami et al., 2009). But in our samples, not all the VEGFC-upregulated cases had metastatic lymph nodes, meanwhile not all the lymphatic metastatic cases had upregulated VEGFC expression (Table 2). So we assumed that because there are lots of pathways contributing to LM, and lymphangiogenesis is just one of them, VEGFC cannot account for all the LM mechanisms in stomach cancer and in these cases lymphangiogenesis played a less important role in LM. This may also be the reason that other VEGFC related factors in our study were not significantly correlated with LM (Table 3). As for CNTN1, which is correlated with cTNM staging (Table 3), there is much to do to reveal its role in stomach cancer LM.

When it comes to clinical and pathological characteristics, first, besides the positive result about CNTN1 mentioned above, SIX1 is positively correlated with age which made us speculate SIX1 has something to do with aging. Second, we found that VEGFC and CNTN1 were both correlated with the tumor size (Table 3). As reported, VEGFC can stimulate the growth of stomach cancer cells (Kodama et al., 2008), which means the role of VEGFC in stomach cancer is far beyond stimulating...
lymphangiogenesis. As forCNTN1, which is reported to be involved in VEGFC/VEGFR3 pathway, it can be induced when VEGFC activates VEGFR3 downstream effectors (Su et al., 2006; Liu et al., 2011) (Figure 1). It would be reasonable to believe that as a downstream factor of VEGFC, CNTN1 could also play critical role in stomach cancer carcinogenesis more than stimulating lymphangiogenesis, which can also be supported by the result that the expression level of VEGFC and CNTN1 were significantly correlated (Table 4).

In our study we found a positive correlation between VEGFC and SIX1 (Table 4), especially in these cases with upregulated VEGFC expression. Wang’s results (Wang et al., 2012) showed that SIX1, an upstream molecular of VEGFC, has several binding domains in genetic promoter region of VEGFC and SIX1 can activate the expression of VEGFC (Figure 1). These results provided underlying mechanism for our finding of the expression association between VEGFC and SIX1. Besides, SIX1 is also correlated with CNTN1 (Table 4), which made us speculate that there is indeed a pathway in stomach cancer involving SIX1/VEGFC/CNTN1 (Figure 1). Some molecular biological research is needed to demonstrate this hypothesis thoroughly.

As we know, MAPK pathway is implicated in stomach cancer (Wu et al., 2010). VEGFC can be induced when this pathway is activated (Tsai et al., 2003; Zhu et al., 2011) (Figure 1). DUSP6 services as the inhibitor of MAKP pathway. So it is assumed that DUSP6 should have reverse correlation with VEGFC expression, however, we saw a positive correlation between DUSP6 and VEGFC in our study (Table 4). Given that there is a complicated negative regulatory feedback loop between ERK1/2 and DUSP6, which also can be transcriptionally regulated by SIX1 (Le Grand et al., 2012) (Figure 1), we thought that the complicity in these important pathways cannot be outlined by single molecule, it is a network that counts.

In conclusions: Our study implied that VEGFC and its related factors, like SIX1, CNTN1 and DUSP6, may play critical role in stomach cancer. There exists an important regulatory crosstalk involving SIX1, VEGFC, CNTN1 and DUSP6 in stomach carcinogenesis and aggressiveness.

Acknowledgements

This work was supported by Grant 81071994 and 81201521 from the National Natural Science Foundation of China.

References

Achen MG, Stacker SA (2008). Molecular control of lymphatic metastasis. Ann NY Acad Sci, 1131, 225-34.

Alitalo K, Carmeliet P (2002). Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell, 1, 219-27.

Amioka T, Kitadai Y, Tanaka S, et al (2002). Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer, 38, 1413-9.

Arigami T, Natsugoe S, Uenosono Y, et al (2009). Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg Oncol, 99, 148-53.

Cao Y (2008). Why and how do tumors stimulate lymphangiogenesis? Lymphat Res Biol, 6, 145-8.

Cejudo-Marín R, Tarrega C, Nunes-Xavier CE, Pulido R (2012). Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function. J Mol Biol, 420, 128-38.

Christensen KL, Patrick AN, McCoy EL, Ford HL (2008). The six family of homeobox genes in development and cancer. Adv Cancer Res, 101, 93-126.

Furukawa T, Tanji E, Xu S, Horii A (2008). Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells. Biochem Biophys Res Commun, 377, 317-20.

Guggenheim DE, Shah MA (2012). Gastric cancer epidemiology and risk factors. J Surg Oncol, 107, 230-6.

Jennbacken K, Vallbo C, Wang W, Damber JE (2005). Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate, 65, 110-6.

Joukov V, Pajusola K, Kaipainen A, et al (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 15, 290-98.

Kodama M, Kitadai Y, Tanaka M, et al (2008). Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res, 14, 7205-14.

Kumar JP (2009). The sine oculis homeobox (SIX) family of transcription factors as regulators of development and disease. Cell Mol Life Sci, 66, 565-83.

Le Grand F, Grifone R, Mourikis P, et al (2012). Six1 regulates stem cell repair potential and self-renewal during skeletal muscle regeneration. J Cell Biol, 198, 815-32.

Liu P, Zhou J, Zhu H, et al (2011). VEGF-C promotes the development of esophageal cancer via regulating CNTN1 expression. Cytokine, 55, 8-17.

Liu Y, Zhang C, Fan J, et al (2011). Comprehensive analysis of clinical significance of stem-cell related factors in renal cell cancer. World J Surg Oncol, 9, 121.

Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods, 25, 402-8.

Mailllet M, Purcell NH, Sargent MA, et al (2008). DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J Biol Chem, 283, 31246-55.

Peng C, Sun Q, Fang Y, et al (2011). VEGF-C antisense oligodeoxynucleotide suppression of invasive ability of the A-549 lung carcinoma cell line. Asian Pac J Cancer Prev, 12, 2097-9.

Su JL, Yang PC, Shiah JY, et al (2006). The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell, 9, 209-23.

Su JL, Yen CJ, Chen PS, et al (2007). The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer, 96, 541-5.

Tsai PW, Shiah SG, Lin MT, et al (2003). Up-regulation of vascular endothelial growth factor C in breast cancer cells by herregulin-beta 1. A critical role of p38/nuclear factor-kappa B signaling pathway. J Biol Chem, 278, 5750-9.

Wang CA, Jedlicka P, Patrick AN, et al (2012). SIX1 induces lymphangiogenesis and metastasis via upregulation of
VEGF-C in mouse models of breast cancer. *J Clin Invest*, **122**, 1895-906.

Wang J, Guo Y, Wang B, et al (2012). Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature. *Mol Biol Rep*, **39**, 11153-65.

Wang Z, Chen Y, Li X, et al (2012). Expression of VEGF-C/VEGFR-3 in human laryngeal squamous cell carcinomas and its significance for lymphatic metastasis. *Asian Pac J Cancer Prev*, **13**, 27-31.

Wu WK, Cho CH, Lee CW, et al (2010). Dysregulation of cellular signaling in gastric cancer. *Cancer Lett*, **295**, 144-53.

Zhu C, Qi X, Chen Y, et al (2011). PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. *J Cancer Res Clin Oncol*, **137**, 1587-94.